NCT02013167 2024-03-05Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)AmgenPhase 3 Terminated405 enrolled 27 charts 1 FDA